Clinical outcomes and quality of life of interventional therapy plus enteral nutrition and chemotherapy in multidisciplinary management for recurrent ovarian cancer with intestinal obstruction

Li Ya; Ma Zhiqiang; Liu Tao; Wu Ming

doi:10.16689/j.cnki.cn11-9349/r.2026.03.015

PDF(842 KB)

Electronic Journal of Metabolism and Nutrition of Cancer ›› 2026, Vol. 13 ›› Issue (3) : 428-433. DOI: 10.16689/j.cnki.cn11-9349/r.2026.03.015

Original Articles

Clinical outcomes and quality of life of interventional therapy plus enteral nutrition and chemotherapy in multidisciplinary management for recurrent ovarian cancer with intestinal obstruction

¹Li Ya, ²Ma Zhiqiang, ³Liu Tao, ⁴Wu Ming

Author information +

History +

Abstract

Objective To explore the effect of interventional therapy combined with enteral nutrition and chemotherapy on the clinical efficacy and quality of life of patients with recurrent ovarian cancer complicated with intestinal obstruction under multidisciplinary cooperation mode. Method The clinical data of 60 patients with recurrent ovarian cancer complicated with intestinal obstruction treated at Beijing Meizhong Airui Cancer Hospital from January 2021 to August 2023 were retrospectively collected. Treatment plans were formulated for all patients within the framework of the MDT mode, and treatment involved the placement of a intestinal obstruction catheter combined with enteral nutrition and chemotherapy. The therapeutic efficacy on intestinal obstruction, anti-tumor efficacy, as well as nutritional indicators, quality of life, and safety before and after treatment were observed. Result After treatment, the total effective rate for intestinal obstruction relief in the 60 patients was 86.67% (52/60), the objective response rate (ORR) was 46.67% (28/60), and the disease control rate (DCR) was 76.67% (46/60). The abnormal rate of hemoglobin was 71.67% (43/60) before treatment and decreased to 40.00% (24/60) after treatment; the abnormal rate of albumin was 83.33% (50/60) before treatment and decreased to 31.67% (19/60) after treatment, with statistically significant differences (P<0.05). Compared with before treatment, the scores of all dimensions of the European Organization for Research and Treatment of Cancer quality of life questionnaire core 30 (EORTC QLQ-C30) improved after treatment (P<0.05). During treatment, the main adverse reactions included myelosuppression in 28 cases (46.67%), nausea and vomiting in 22 cases (36.67%), diarrhea in 12 cases (20.00%), and abnormal liver function in 8 cases (13.33%). All symptoms were alleviated after symptomatic treatment, and no treatment-related deaths occurred. Conclusion Under the MDT mode, the combination of interventional therapy, enteral nutrition, and chemotherapy for the treatment of recurrent ovarian cancer complicated with intestinal obstruction suggests that this comprehensive treatment regimen helps alleviate obstructive symptoms and improve patients’ nutritional indicators and quality of life.

Key words

Recurrent ovarian cancer / Cancer-associated intestinal obstruction / Multidisciplinary team mode / Interventional therapy / Enteral nutrition / Chemotherapy / Quality of life / Safety

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Li Ya, Ma Zhiqiang, Liu Tao, Wu Ming. Clinical outcomes and quality of life of interventional therapy plus enteral nutrition and chemotherapy in multidisciplinary management for recurrent ovarian cancer with intestinal obstruction[J]. Electronic Journal of Metabolism and Nutrition of Cancer. 2026, 13(3): 428-433 https://doi.org/10.16689/j.cnki.cn11-9349/r.2026.03.015

References

[1] THULL T, KEMPTON D. Ovarian cancer: a review for primary care providers[J]. JAAPA,2024,37(7):32-36.
[2] CHEN W C, HUANG H J, YANG L Y, et al. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer[J]. Biomed J,2022,45(5):821-827.
[3] LIBERTO J M, CHEN S Y, SHIH I M, et al. Current and emerging methods for ovarian cancer screening and diagnostics: a comprehensive review[J]. Cancers (Basel),2022,14(12):2885.
[4] JANSEN J, OLDENBURGER E, JANSEN J, et al. Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study[J]. Ann Med Surg (Lond),2023,85(5):1539-1545.
[5] 刘胜中,张敏伟,张子秋,等.X线引导下置入肠梗阻导管治疗妇科恶性肿瘤所致恶性肠梗阻[J].中国介入影像与治疗学,2024,21(6):334-337.
[6] BEKHOR E Y, KLEIN E, SHMILOVICH H, et al. Self-expanding metallic stent insertion for malignant bowel obstruction secondary to gynecologic malignancies: a retrospective analysis: SEMS for gynecological MBO is efficient[J]. Surg Endosc,2025,39(2):1147-1152.
[7] PANIAGUA GARCÍA-SEÑORÁNS M, SÁNCHEZ SANTOS R, et al. Stent as bridge to surgery decreases postoperative complications without worsening oncological outcomes: retrospective unicentric cohort study and stent placement protocol[J]. Surg Endosc,2023,37(8):6298-6307.
[8] SHAO Z, FU L, LU Y, et al. Ovarian cancer and malnutrition: a literature review[J]. Transl Cancer Res,2025,14(5):3239-3254.
[9] RINNINELLA E, FAGOTTI A, CINTONI M, et al. Nutritional interventions to improve clinical outcomes in ovarian cancer: a systematic review of randomized controlled trials[J]. Nutrients,2019,11(6):1404.
[10] 牛玉英,朱兴春,唐鸥鹭.肠道金属支架联合肠内-肠外营养对结肠癌伴肠梗阻的应用效果分析[J/CD].肿瘤综合治疗电子杂志,2023,9(1):58-62.
[11] 杨守梅,李苏宜.癌性机械性肠梗阻内科临床技术路线[J].肿瘤学杂志,2023,29(4):276-280.
[12] EL HOUSHEIMI A, TATO VARELA S, KUHN W C. Prognosis and therapy of ovarian cancer, part 3: follow-up care, recurrence, and screening, the full round circle[J]. Oncol Res Treat,2026,49(3):150-164.
[13] MURPHY A D, PORTER C, WHITE A, et al. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial[J]. Int J Gynecol Cancer,2024,34(7):1034-1040.
[14] 周琦,吴小华,刘继红,等.卵巢恶性肿瘤诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(7):739-749.
[15] 于世英,王杰军,王金万,等.晚期癌症患者合并肠梗阻治疗的专家共识[J].中华肿瘤杂志,2007,29(8):637-640.
[16] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[17] KING M T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30[J]. Qual Life Res,1996,5(6):555-567.
[18] FAROOQ S M, KARAKOUSIS C G, KROUSE S R. Malignant bowel obstruction: historical lessons, current trends, and future directions[J]. Surgical Oncology Insight,2024,1(2):100046.
[19] ONYIEGO A, MAYKEL J. Contemporary management of malignant bowel obstruction[J]. Clin Colon Rectal Surg,2025,38(5):327-333.
[20] IDAIKKADAR P, GEORGIOU A, SKENE S, et al. Non-surgical management of malignant bowel obstruction in advanced ovarian cancer patients: a systematic review and meta-analysis[J]. Am J Hosp Palliat Care,2022,39(7):838-846.
[21] LIU J, REN W, ZAN N, et al. Advanced ovarian cancer with malignant bowel obstruction treated with multidisciplinary therapy resulting in long progression-free survival: a case report[J]. BMC Womens Health,2025,26(1):10.
[22] 刘华,张小田.乙状结肠癌并发恶性肠梗阻处理的临床决策讨论[J].中国肿瘤临床,2022,49(9):467-473.
[23] DUAN H, TAO R, QIN J. Development and validation of a clinical prognosis prediction model for malignant intestinal obstruction: a retrospective cohort study[J]. Sci Rep,2025,15(1):11550.
[24] NERI B, CITTERIO N, SCHIAVONE S C, et al. Malignant bowel occlusion: an update on current available treatments[J]. Cancers (Basel),2025,17(9):1522.
[25] 付艳,孙志佳,李东惠,等.贝伐珠单抗联合化疗治疗晚期卵巢癌所致粘连性肠梗阻的疗效观察[J].现代肿瘤医学,2021,29(15):2682-2686.
[26] MU C, CHEN L. A retrospective evaluation of short-term results from colonic stenting as a bridge to elective surgery versus emergency surgery for malignant colonic obstruction[J]. Sci Rep,2023,13(1):1600.
[27] YAMAMOTO M, OSUGI N, NAKAMATSU D, et al. Short-term efficacy and long-term limitations of self-expandable metallic stent placement for colorectal obstruction due to extracolonic malignancies[J]. DEN Open, 2025, 6(1): e70234.
[28] SANGUANWONGTHONG K, SUPRASERT P. Prevalence of malnourishment and predictive factors associated with the nutritional status of gynecologic cancer patients undergoing chemotherapy: a cross-sectional analysis[J]. Obstet Gynecol Sci,2022,65(3):234-243.
[29] NATES J L, PÈNE F, DARMON M, et al. Septic shock in the immunocompromised cancer patient: a narrative review[J]. Crit Care,2024,28(1):285.
[30] TIAN X, LIU Y, ZHANG J, et al. Efficacy of a wechat-based, multidisciplinary, full-course nutritional management program on the nutritional status of patients with ovarian cancer undergoing chemotherapy: randomized controlled trial[J]. JMIR Mhealth Uhealth, 2024, 12: e56475.
[31] MAURER T, BELAU M H, ZYRIAX B C, et al. Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial[J]. BMC Cancer,2024,24(1):1379.
[32] 何杨,侯志冰,王烈,等.床旁盲插经鼻型肠梗阻导管联合续贯肠内营养治疗粘连性小肠梗阻的疗效[J].实用医学杂志,2025,41(8):1175-1180.
[33] 郑昕,陶素萍,游继红,等.奥拉帕利联合贝伐珠单抗治疗铂敏感复发性卵巢癌患者疗效及对血清HE4、CA125和CTC水平的影响[J].中国妇幼健康研究,2025,36(8):91-97.
[34] 宋俊霞,丰树菊.卵巢癌根治术联合TP方案化疗治疗卵巢癌的临床效果[J].实用癌症杂志,2025,40(8):1254-1257.
[35] MANIVANNAN P, CHAKKALAKKOOMBIL S V, GOCHHAIT D, et al. Targeting autophagy in platinum-sensitive relapsed ovarian cancer: randomized phase II trial of hydroxychloroquine with chemotherapy with biomarker correlation[J]. Discov Oncol,2025,16(1):203.